CATALYSTYahoo • 2d ago
Can Axon Stock Jump 50%?For questions about this article or underlying research, email help@trefis.com.
Why CDRE Stock surged +3.81% Today — RQD Quant Desk Flash
$31.10 +3.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $31.39
Cadre Holdings Inc. (CDRE) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (43% profit margin, 11% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $1.33B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $31.39 (+0.93%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CDRE)Realized 20D OHLCV Swing Band: ±9%
Deterministic 5-Pillar Attribution (74/100 Composite)
🔍 WHY CDRE SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 9.3% FCF Margin ($56.8M FCF) & 42.5% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (20% of score)
Altman Z-Score 3.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution14/20 pts (-6 pt drag)
Cannibal Buyback (-1.80% YoY Shares) & executive Form 4 sales trim 6 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$24.55+7.5% Next Q
66
Q2 (-2Q)Grade B-$26.38+13.7% Next Q
69
Q3 (-1Q)Grade B$29.99+3.7% Next Q
71
CurrentGrade B$31.10+7.3% Hist 90D α
74
Trajectory: B- (66) → B (74)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CDRE Bull Thesis Could Fail
Even with a 74/100 (B) score, CDRE faces multiple-compression risk if 30.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 40.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.96) or 200D SMA ($32.22) invalidates the momentum regime and cuts Target Base ($33.34) toward Bear Floor ($25.50).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CDRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CDRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CDRE Stock surged +3.81% Today — RQD Quant Desk Flash
Cadre Holdings Inc. (CDRE) surged +3.81% to $31.10, trading at 28% of its 52-week range ($24.07 – $48.76). High-quality cash engine (43% profit margin, 11% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 28% of its 52-week range ($24.07 – $48.76) with RSI-14 at 65 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9% around $31.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 42.5% gross margin and $56.8M annual free cash flow.
Live CDRE Headlines & Catalysts
MARKET WIREYahoo • 3d ago
1 surging stock with competitive advantages and 2 that underwhelmGreat things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit
MARKET WIREYahoo • 4d ago
Is Axon Stock Increasing Your Market Risk?For questions about this article or underlying research, email help@trefis.com.
MARKET WIREYahoo • 5d ago
Hubbell (HUBB) Q3 Earnings and Revenues Surpass EstimatesHubbell (HUBB) delivered earnings and revenue surprises of +2.78% and +0.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
RISK WATCHYahoo • 8d ago
Cadre (CDRE) Stock Could Be A Bargain On Cash FlowCadre Holdings shares closed at US$29.99 recently after a mixed run that included a sharp decline over the past year and a shorter burst of gains. With that backdrop, the open question is whether the current price makes
MARKET WIREYahoo • 10d ago
Cadre Holdings Announces Third Quarter 2026 Earnings and Conference Call InformationJACKSONVILLE, Fla., October 22, 2026--Cadre Holdings, Inc. (NYSE: CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforce
CATALYSTYahoo • 12d ago
Cadre Holdings Declares Quarterly Dividend of $0.10 Per ShareJACKSONVILLE, Fla., October 20, 2026--Cadre Holdings, Inc. (NYSE: CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforce
RISK WATCHYahoo • 12d ago
Has Buying Axon Stock's Dips Paid Off?Axon Enterprise (AXON) shares declined 16.6% between their September 22 close and October 19, 2026. The sharpest daily loss took place on October 16, when the stock gave up 6.4%. A rapid slide leaves some investors looki
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CDRE Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CDRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.89%📐 HORIZONTAL RANGE
2026-10-30O $31.14H $31.49L $30.03C $31.10VOL 320.5K
RES: $42.91SUP: $22.98SMA50: $27.96SMA200: $32.22
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CDRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
23.3%/yr Implied 5Y Growth
vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CDRE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CDRE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CDRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CDRE)
Health Care Rank #55 of 1016
⚔️ ENOV vs CDRE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CDRE vs. ENOV, ESTA, AVR, SMTI)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cadre Holdings Inc. (CDRE) ranks #55 by composite RQD confidence (74/100, grade B) and #323 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CDRE
ACTIVE
Cadre Holdings Inc. | B | 74/100 | 30.2x | 42.5% | 11.0% | +3.81% | $1.33B | Benchmark Subject |
| ENOV Enovis Corporation | D | 46/100 | — | 59.8% | -32.7% | +4.11% | $1.32B | /enov-vs-cdre → |
| ESTA Establishment Labs Holdings Inc. | E | 34/100 | — | 69.3% | -15.8% | -0.81% | $2.04B | /esta-vs-cdre → |
| AVR Anteris Technologies Global Corp. | D- | 36/100 | — | 70.3% | -35.0% | +5.25% | $625.9M | /avr-vs-cdre → |
| SMTI Sanara MedTech Inc. | D+ | 57/100 | 8.1x | 92.7% | 16.3% | +0.11% | $302.4M | /smti-vs-cdre → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860543In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cadre Holdings Inc. (CDRE) reported GAAP revenue of $610.3M (+7.5% vs. FY2024 revenue of $567.6M , and +26.5% cumulative change since FY2023) , GAAP net income of $44.1M, operating cash flow of $63.7M, and free cash flow of $56.8M (+117.7% YoY). On the balance sheet, CDRE closed FY2025 with $770.0M in total assets against $291.0M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $610.3M | $44.1M | $63.7M | $56.8M | $770.0M | $291.0M |
| FY2024 (FY) | 2024-12-31 | $567.6M | $36.1M | $31.8M | $26.1M | $652.7M | $211.8M |
| FY2023 (FY) | 2023-12-31 | $482.5M | $38.6M | $73.2M | $73.2M | — | — |
3. CDRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CDRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Cadre Holdings Inc. (NYSE: CDRE) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $31.10 (+3.81% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CDRE ranks #55 in composite RQD confidence.
How does CDRE compare to ENOV and ESTA in the Health Care sector?
Within the Health Care sector (Industrial Specialties), CDRE carries a Roarable B (74/100 RQD), trailing P/E of 30.2x, gross margin of 42.5%, and ROIC of 11.0%. By comparison, ENOV (Enovis Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -32.7%, cap $1.32B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -15.8%, cap $2.04B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CDRE?
Per CDRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860543), Cadre Holdings Inc. generated $610.3M in revenue (+7.5% YoY), $44.1M in net income, and $56.8M in free cash flow against $770.0M in total assets and $291.0M in total debt. Key quantitative strengths: Strong cash generator (43% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CDRE trading relative to its 50-day, 200-day, and 52-week technical levels?
CDRE last traded at $31.10 (+3.81% on volume of 433,055 shares), positioning the stock +11.23% above its 50-day simple moving average ($27.96) and -3.48% below its 200-day simple moving average ($32.22). Across its 52-week range of $24.07 to $48.76, CDRE sits at the 28.5% percentile with a 14-day RSI of 65.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.0% ($28.30 to $33.90).
CDRE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CDRE stock moving today?
Why CDRE Stock surged +3.81% Today — RQD Quant Desk Flash. High-quality cash engine (43% profit margin, 11% return on capital) with steady institutional support.